Of all medications currently being sold in the United States, Lipitor is one of the most commonly used brand-name medications. This cholesterol lowering statin medication had generated an estimated $125 billion in sales for Pfizer before the drug became available as a generic in 2011. The medication has been heavily promoted in direct-to-consumer advertising campaigns, encouraging patients to speak to their doctors about whether they need to be placed on Lipitor to maintain their health. The advertisements were directed to the public, including women who did not have many risk factors for heart disease and were not at high risk of a cardiac event. Thus, women really received no long-term benefit from taking the drug.
According to several lawsuits filed in 2013, Pfizer knew or reasonably should have known in 1997 that there was a connection between Lipitor and diabetes before the drug was even placed on the market. However, there was no warning added to the label until February 2012. This was after the U.S. Food and Drug Administration’s (FDA) Division of Metabolism and Endocrinology Products requested that a warning be provided for consumers and the medical community. Even then, the warning never actually mentioned Type 2 diabetes, stating instead: “Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including LIPITOR.”
It’s alleged in the lawsuits that until the February 2012 label change, Lipitor’s label never warned patients of any potential relation between changes in blood sugar levels and taking Lipitor. Lawsuits further allege that despite the February 2012 label change, Lipitor’s label continues to fail to warn consumers of the serious risk of developing Type 2 diabetes when using Lipitor. Frank Woodson, a lawyer in our firm’s Mass Torts Section, is investigating Lipitor claims and can be reached at 800-898-2034 or by email at Frank.Woodson@beasleyallen.com.
Source: About Lawsuits website
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.